Damienne Marcus
Overview
Explore the profile of Damienne Marcus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Wiel A, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, et al.
Mol Cancer Ther
. 2021 Oct;
20(12):2372-2383.
PMID: 34625504
Hypoxia-activated prodrugs (HAP) are a promising class of antineoplastic agents that can selectively eliminate hypoxic tumor cells. This study evaluates the hypoxia-selectivity and antitumor activity of CP-506, a DNA alkylating...
2.
Marcus D, Lieverse R, Klein C, Abdollahi A, Lambin P, Dubois L, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33806808
Radiotherapy (RT) has been shown to interfere with inflammatory signals and to enhance tumor immunogenicity via, e.g., immunogenic cell death, thereby potentially augmenting the therapeutic efficacy of immunotherapy. Conventional RT...
3.
Olivo Pimentel V, Marcus D, van der Wiel A, Lieuwes N, Biemans R, Lieverse R, et al.
J Immunother Cancer
. 2021 Mar;
9(3).
PMID: 33688020
Background: Poorly immunogenic tumors are hardly responsive to immunotherapies such as immune checkpoint blockade (ICB) and are, therefore, a therapeutic challenge. Combination with other immunotherapies and/or immunogenic therapies, such as...
4.
Olivo Pimentel V, Yaromina A, Marcus D, Dubois L, Lambin P
J Immunol Methods
. 2020 Oct;
487:112899.
PMID: 33068606
T cell immunotherapies have shown great promise in patients with advanced cancer disease, revolutionizing treatment. T cell cytotoxicity is crucial in its efficacy, therefore developing ex vivo methods testing tumor...
5.
Mowday A, Lieuwes N, Biemans R, Marcus D, Rezaeifar B, Reniers B, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32549357
Glioblastoma multiforme (GBM) is a common and aggressive malignant brain cancer with a mean survival time of approximately 15 months after initial diagnosis. Currently, the standard-of-care (SOC) treatment for this...
6.
Sanduleanu S, van der Wiel A, Lieverse R, Marcus D, Ibrahim A, Primakov S, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32455922
Hypoxia-a common feature of the majority of solid tumors-is a negative prognostic factor, as it is associated with invasion, metastasis and therapy resistance. To date, a variety of methods are...
7.
Lieverse R, Marcus D, van der Wiel A, Van Limbergen E, Theys J, Yaromina A, et al.
Mol Oncol
. 2020 May;
14(7):1555-1568.
PMID: 32386436
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid...
8.
Lambin P, Lieverse R, Eckert F, Marcus D, Oberije C, van der Wiel A, et al.
Semin Radiat Oncol
. 2020 May;
30(2):187-193.
PMID: 32381298
There is now strong clinical and preclinical evidence that lymphocytes, for example, CD8 T cells, are key effectors of immunotherapy and that irradiation of large blood vessels, the heart, and...
9.
Rogers W, Thulasi Seetha S, Refaee T, Lieverse R, Granzier R, Ibrahim A, et al.
Br J Radiol
. 2020 Feb;
93(1108):20190948.
PMID: 32101448
Historically, medical imaging has been a qualitative or semi-quantitative modality. It is difficult to quantify what can be seen in an image, and to turn it into valuable predictive outcomes....
10.
Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
Spiegelberg L, van Hoof S, Biemans R, Lieuwes N, Marcus D, Niemans R, et al.
Radiother Oncol
. 2019 Aug;
141:247-255.
PMID: 31431383
Background And Purpose: Esophageal cancer incidence is increasing and is rarely curable. Hypoxic tumor areas cause resistance to conventional therapies, making them susceptible for treatment with hypoxia-activated prodrugs (HAPs). We...